甲胎蛋白联合α-L-岩藻糖苷酶及高尔基体膜蛋白-73检测对原发性肝癌的早期诊断价值  

Clinical value of AFP, AFU and GP73 combined detection in early diagnosis of primary hepatic cancer

作　　者：杨春玲[1] 夏薇[1] 宋海春[1] 迟芳萍[1] 

机构地区：[1]吉林省吉林市中心医院核医学科,132011

出　　处：《中国实用医刊》2012年第3期16-17,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨血清甲胎蛋白（AFP）、α-L-岩藻糖苷酶（AFU）及高尔基体膜蛋白-73（GP73）在原发性肝癌早期诊断中的应用价值。方法对56例原发性肝癌患者、85例良性肝病患者和60例健康体检者联合检测，用放射免疫法检测各组血清中甲胎蛋白含量，用速率法测定各组血清中AFU含量，用酶联免疫吸附试验测定各组血清中GP73含量。结果原发性肝癌（PHC）组血清AFP、AFU和GP73水平均明显高于良性肝病组及健康对照组，差异有统计学意义（P〈0．05）；PHC患者血清AFP、AFU和GP73阳性率分别为66．1％、76．8％、82．1％，AFP与AFU、GP73联检其阳性率可提高到94．6％。结论联合检测AFP、AFU、GP73可提高PHC的诊断效率，尤其是AFP阴性PHC的诊断效率，对PHC的早期诊断有一定指导意义。Objective To investigate the clinical values of combined detection of serum AFP, AFU and GP73 levels in the early diagnosis of primary hepatic cancer. Methods The serum AFP, AFU and GP73 levels in 56 patients with primary hepatic cancer, 85 patients with hepatic benign disease and 60 healthy persons were measured by radio immunologic methods, speed method and enzyme linked im- munosorbent assay （ELISA）. Results The levels of serum AFP, AFU and GP73 of primary hepatic cancer patients were significantly higher than those of hepatic benign disease patients and healthy controis, and there were significant differences （P 〈 0.05 ）, the positive rates of serum AFP, AFU and GP73 were 66. 1%, 76.8%, 82. 1% in patients with primary hepatic cancer. With combined detection of serum AFP, AFU and GP73, the positive rate of primary hepatic cancer could be enhanced to 94. 6%. Conclusions The combined detection of serum AFP, AFU and GP73 levels could increase the diagnostic sensitivity of primary hepatic cancer, especially primary hepatic cancer with negative AFP, it is valuable for the early diagnosis of primary hepatic cancer.

关 键 词：原发性肝癌 早期诊断 血清肿瘤标志物 

分 类 号：R735.7[医药卫生—肿瘤]